Personal cell therapy for advanced throat cancer linked to HPV
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a special type of immune cell therapy for advanced throat cancer tied to HPV infection. Your own immune cells are reprogrammed in a lab to better attack cancer cells, then given back to you. It aims to help people whose cancer has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of throat cancer that is linked to the HPV virus, specifically HPV type 16 or 18.
- Your cancer must have already been treated with at least one standard treatment like chemo or immunotherapy, and it still came back or spread.
- You must have a specific immune marker (HLA-A*0201) that the study checks for.
- You need to be fairly active and able to take care of yourself (a doctor's scale of 0 or 1).
- Your cancer must be measurable on scans, meaning there is at least one tumor that can be seen clearly.
- Your heart, kidneys, liver, and blood counts need to be in a healthy enough range for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment using your own immune cells (called SCG142) that are specially trained to attack cancer cells linked to HPV 16 or 52. It may help people with advanced squamous cell cancers who have not gotten better with standard treatments.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
Hear when a new Oropharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.